MicroRNA replacement therapy in cancer

Mollaei, Homa; Safaralizadeh, Reza; Rostami, Zeinab

doi:10.1002/jcp.28058

Cited by 211 publications

(161 citation statements)

References 228 publications

(287 reference statements)

Supporting

Mentioning

156

Contrasting

Unclassified

Order By: Relevance

“…In pathological conditions, MiRNAs can negatively regulate gene expression and they are associated with tumor growth, apoptosis, invasion, and metastasis. In the past, several studies have indicated the ability of miRNAs in the inhibition of tumors as a critical option for the improvement of cancer therapy [4,5]. Tumor activator miRNAs, called oncomiRs, are overexpressed in various cancers.…”

mentioning

confidence: 99%

MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers

Kooshkaki

Rezaei

Rahmati

et al. 2020

IJMS

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small and non-coding RNAs that display aberrant expression in the tissue and plasma of cancer patients when tested in comparison to healthy individuals. In past decades, research data proposed that miRNAs could be diagnostic and prognostic biomarkers in cancer patients. It has been confirmed that miRNAs can act either as oncogenes by silencing tumor inhibitors or as tumor suppressors by targeting oncoproteins. MiR-144s are located in the chromosomal region 17q11.2, which is subject to significant damage in many types of cancers. In this review, we assess the involvement of miR-144s in several cancer types by illustrating the possible target genes that are related to each cancer, and we also briefly describe the clinical applications of miR-144s as a diagnostic and prognostic tool in cancers.Int. J. Mol. Sci. 2020, 21, 2578 2 of 23 of a mRNA molecule [3]. MiRNAs indicate a new perspective in the study of cancers. More than 50% of miRNA genes were discovered to be located within the genomic regions that are involved in cancers, suggesting their role in human cancer pathogenesis. In pathological conditions, MiRNAs can negatively regulate gene expression and they are associated with tumor growth, apoptosis, invasion, and metastasis. In the past, several studies have indicated the ability of miRNAs in the inhibition of tumors as a critical option for the improvement of cancer therapy [4,5]. Tumor activator miRNAs, called oncomiRs, are overexpressed in various cancers. On the contrary, suppressive tumor miRNAs are underexpressed [6][7][8]. Among several miRNAs assessed, miR-144s seem to have a role in several cancers. These miRNAs are located in the chromosomal region 17q11.2, being significantly destroyed in many types of cancers. The predicted stem-loop structure of miR-144s recognized by the miRBase (http://mirbase.org/) is shown in Figure 1A. The miR-144 hairpin gives rise to the "guide strand" miR-144-5p and the sister "passenger" strand miR-144-3p ( Figure 1B).

show abstract

mentioning

confidence: 99%

MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers

Kooshkaki

Rezaei

Rahmati

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Interestingly, it could also be possible to restore the expression of a tumor suppressor miRNA by inserting genes coding for miRNAs into viral constructs, such as adenovirus-associated vectors. The aim of anti-miRs approaches is to silence oncogenic miRNAs using anti-miR oligonucleotides, miRNA sponges, miRNA masking, and small RNA inhibitors [102,103]. Anti-miR oligonucleotides are chemically modified antisense oligonucleotides.…”

Section: Mirnas As Therapeutic Targetsmentioning

confidence: 99%

Cell-Free microRNAs as Potential Oral Cancer Biomarkers: From Diagnosis to Therapy

Rapado‐González

López‐López

López-Cedrún

et al. 2019

Cells

View full text Add to dashboard Cite

Oral cavity cancer is the most frequent malignancy of the head and neck. Unfortunately, despite educational interventions for prevention and early diagnosis, oral cancer patients are often diagnosed in advanced stages associated with poor prognosis and life expectancy. Therefore, there is an urgent need to find noninvasive biomarkers to improve early detection of this tumor. Liquid biopsy has emerged as a valuable tool in medical oncology which provides new horizons for improving clinical decision making. Notably, cell-free microRNAs (miRNAs), a class of short non-coding RNAs, are emerging as novel noninvasive cancer biomarkers. Here, we provide an overview of the potential clinical application of cell-free miRNAs as diagnostic, prognostic, and therapeutic biomarkers in oral cancer.

show abstract

“…Moreover, the functions of miRNAs are involved in the occurrence, development and metastasis of tumors. 7 For instance, Mirzaei et al reported that miR-29b has signi cant tumor-suppressive effects on chronic lymphocytic leukemia (CLL). 8 In addition, Zhou Y et al discovered that miR-130a acts as an oncogenic miRNA in gastric cancer.…”

Section: Introductionmentioning

confidence: 99%

A novel seven-microRNA signature predicts prognosis in colorectal adenocarcinoma

Jiang¹,

Xie²,

Jiang³

2020

Preprint

View full text Add to dashboard Cite

Background Colorectal carcinoma, primarily colorectal adenocarcinoma (CRA), is one of the most common malignancies, ranking third, while contributing the second cause of cancer death in the world. MicroRNAs, a type of non-coding RNA, play an important role in regulating cancer-related cell biology. To simply and accurately predict survival risk for CRA patients, we identified a novel seven-miRNA signature. The microRNA (miRNA) expression profiles along with clinical data of 512 CRA patients were downloaded from The Cancer Genome Atlas (TCGA) database, and 415 patients with complete clinical information were further divided into training set and test set randomly. To construct the prognostic signature in the training set, a series of Cox regression analyses were performed, including univariate regression, least absolute shrinkage and selectionator operator (LASSO) - Cox regression, and multivariate regression. Results Seven predictive miRNAs (miR-153-2, miR-3199-2, miR-144, miR-887, miR-561, miR-3684, and miR-505) were ultimately screened. The ROC curves for 5-year survival in the training set, test set and entire set were 0.889, 0.742, and 0.816, respectively. Kaplan-Meier analysis results of the three sets all showed p <0.05. Further analyses demonstrated that the signature was an independent prognostic risk factor for CRA patients, and its predictive ability was superior to age and TNM stage. Functional enrichment analysis revealed that p53 and ErbB pathways were related to the prognostic regulation of miRNAs in the signature in CRA patients.Conclusion Our study demonstrated the potential of this novel seven-miRNA signature to independently predict overall survival in patients with CRA. Functional enrichment analysis further revealed the possible regulatory role of miRNAs in the signature in CRA-related cell biological processes and signaling pathways.

show abstract

MicroRNA replacement therapy in cancer

Cited by 211 publications

References 228 publications

MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers

MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers

Cell-Free microRNAs as Potential Oral Cancer Biomarkers: From Diagnosis to Therapy

A novel seven-microRNA signature predicts prognosis in colorectal adenocarcinoma

Contact Info

Product

Resources

About